CTLA4 and melanoma: Abscopal response rates (ARRs) of 51-53% were further identified in small cohorts of patients with advanced melanoma who progressed an anti-CTLA-4 ICI (Ipilimumab) or an anti-PD-1 ICI (Nivolumab or Pembrolizumab) after they received intra- or extra-cranial hypofractionated RT (228, 229).